Interleukin 17-producing helper T cells (T H 17 cells) have a major role in protection against infections and in mediating autoimmune diseases, yet the mechanisms involved are incompletely understood. We found that interleukin 26 (IL-26), a human T H 17 cell-derived cytokine, is a cationic amphipathic protein that kills extracellular bacteria via membrane-pore formation. Furthermore, T H 17 cell-derived IL-26 formed complexes with bacterial DNA and self-DNA released by dying bacteria and host cells. The resulting IL-26-DNA complexes triggered the production of type I interferon by plasmacytoid dendritic cells via activation of Toll-like receptor 9, but independently of the IL-26 receptor. These findings provide insights into the potent antimicrobial and proinflammatory function of T H 17 cells by showing that IL-26 is a natural human antimicrobial that promotes immune sensing of bacterial and host cell death.
Human interleukin 17-producing helper T cells 7 (T H 17 cells) are a subset of T cells that drive inflammatory responses by producing interleukin 17A (IL-17A), IL-17F, IL-21, IL-22 and IL-26 (refs. 1-3).
Defective T H 17 cell responses in patients deficient in the transcription factor STAT3 have been associated with increased susceptibility to infection by Staphylococcus aureus and Streptococcus pyogenes 4, 5 , which indicates that this T cell subset has a major role in the defense against extracellular bacterial infections, particularly in skin and mucosal surfaces. However, excessive T H 17 cell responses can drive chronic inflammation and the development of autoimmunity in predisposed individuals. T H 17 cell-associated cytokines are indeed associated with disease activity and were found to be present in increased amounts in the skin of subjects with psoriasis, in the intestine of individuals with Crohn's disease, in the brain of people with multiple sclerosis and in the synovium of people with rheumatoid arthritis and ankylosing spondylitis compared with healthy individuals 6 . Furthermore, variants of genes involved in IL-23-induced T H 17 cell differentiation have been identified as susceptibility factors in psoriasis, multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis and Crohn's disease, which suggests a genetic basis for the enhanced T H 17 cell responses in these diseases 6 .
The mechanisms by which T H 17 cell cytokines drive antimicrobial and inflammatory responses are incompletely understood. IL-17A and IL-17F induce the expression of various CXC chemokines in epithelial cells, which drives the recruitment of neutrophils and monocytes 7 . IL-22 induces the proliferation of epithelial cells and is involved in epidermal remodeling 8 . IL-22 also cooperates with IL-17 to activate epithelial cells and induce the production of antimicrobial peptides 8 . IL-21 does not have a direct inflammatory role but amplifies and stabilizes the development of T H 17 cells 9 . The functions of IL-26, a 19-kDa α-helical protein that belongs to the IL-20 cytokine family, are less well characterized. IL-26 was first identified in herpesvirus saimiri-transformed T cells 10 and was subsequently found to be conserved in most vertebrate species but absent in mice 11 . Like other T H 17 cell cytokines, IL-26 shows high expression in psoriatic skin lesions 1 , colonic lesions from individuals with inflammatory bowel disease 12 and synovia of individuals with rheumatoid arthritis 13 , and it is strongly associated with inflammatory activity. A risk locus containing IL26 and single-nucleotide polymorphisms within the IL26 gene region have been associated with multiple sclerosis 14 , rheumatoid arthritis 15 and inflammatory bowel disease 16 , which suggests a particularly important role for IL-26 in T H 17 cell-mediated inflammatory disease.
IL-26 signals through the IL-10R2-IL-20R1 heterodimeric receptor, which is expressed exclusively by epithelial cells 17, 18 . Via its receptor, IL-26 inhibits the proliferation of intestinal epithelial cells and, in parallel, induces expression of immunosuppressive IL-10, but also of the proinflammatory cytokines tumor necrosis factor (TNF) and .
How these functions fit with the proinflammatory role of IL-26 in the context of T H 17 cell responses remains unclear. Here we identified a distinctive cationic, amphipathic and multimeric structure of IL-26 that enabled T H 17 cells to engage in direct antimicrobial activity. This function was mediated by the ability of IL-26 to directly kill extracellular bacteria through pore formation. Furthermore, IL-26 was found to form complexes with extracellular DNA released by dying bacteria and host cells and to promote Toll-like receptor 9 (TLR9) activation of plasmacytoid dendritic cells (pDCs), providing evidence for a potent proinflammatory function of T H 17 cells.
RESULTS

IL-26 is a cationic and amphipathic multimeric protein
Our sequence analysis of IL-26 showed unusual cationicity of this cytokine (calculated charge of +18.1 at pH 7 and isoelectric point of 10.4), as previously described 17 . The majority of the cationic charges were found to be contained in, or adjacent to, two of the six predicted helices of the protein, helices B and E, which contain three arginines and seven lysines (Supplementary Fig. 1a ). Three-dimensional modeling of the protein showed that helices B and E were close to each other (Fig. 1a) , which led to cluster formation and surface exposure of the cationic residues (Fig. 1b) . On the opposite side of this cluster, we observed a hydrophobic patch (helix A) composed of several hydrophobic side chains (alanine 23, isoleucine 26, alanine 29, tryptophan 30 and alanine 33) (Fig. 1b) . The predominance of polar (cationic) residues on one side of the molecule and hydrophobic amino acids on the opposite side indicated that IL-26 is a cationic amphipathic protein. In contrast, IL-22, a close homolog of IL-26 with 27% amino acid identity, has a net charge of +0.2 and an even distribution of cationic, anionic and hydrophobic residues across the surface of the molecule 19 (Fig. 1b) .
To gain further insights into the structure of IL-26, we carried out small-angle X-ray scattering analysis of recombinant human IL-26 (rhIL-26). IL-26 not only formed dimers but also was able to form higher-degree multimers ( Fig. 1c and Supplementary Fig. 1b,c) . This represented an atypical structure compared with close homologs IL-10 and IL-22, which can only dimerize. IL-26 multimers were found to adopt a beads-on-string shape ( Fig. 1c and Supplementary  Fig. 1b,c) , which gave rise to elongated structures. This structure is distinct from the dimeric structure of IL-22, which is compact and results from extensive interactions among helices A, B and F of two monomers 19 . The structure of IL-26 is also distinct from the compact arm-exchange structure of IL-10 dimers 20 , which results from the exchange of helices E and F between two monomers. The absence of arm-exchange dimers in IL-26 is in agreement with the fact that proline 113 of IL-10, a key residue for the arm exchange in IL-10, is not conserved in IL-26. Moreover, the positions of IL-26 cysteines 11 and 100 and of cysteines 58 and 103 in the 3D homology model suggest that these residues form two disulfide bonds to stabilize the helices of IL-26, rather than allowing an arm-exchanged conformation (Supplementary Fig. 1d ). Thus, IL-26 is a highly cationic and amphipathic protein that forms elongated multimers, representing a highly atypical structure compared with the structures of other cytokines from the same family. Because IL-26 monomers or dimers would be sufficient for binding to the dimeric IL-26 receptor, the formation of multimeric structures suggests a functional adaptation of IL-26 to a specialized task.
IL-26 kills extracellular bacteria by pore formation Because an amphipathic structure, the clustering of cationic charges and the formation of multimers are hallmarks of naturally occurring antimicrobial peptides 21 , we asked whether IL-26 has antimicrobial properties. Using microbroth dilution assays, we found that 5-10 µM rhIL-26 inhibited the growth of several gram-negative bacterial strains, including Pseudomonas aeruginosa (ATCC 27853, PA14), Escherichia coli (O1:K1:H7, O18:K1:H7, O111:B4, O111:K58:H2) and Klebsiella pneumoniae (O1:K2), as well as gram-positive S. aureus (ATCC 6538) ( Fig. 2a and Supplementary Fig. 2a) . No inhibition of colony formation was observed with Enterococcus faecalis or Candida albicans at IL-26 concentrations up to 50 µM (Table 1) . rhIL-26, but not rhIL-17 or rhIL-22, efficiently inhibited P. aeruginosa colony formation at a concentration of 10 µM (Fig. 2b) . The observed inhibition of colony formation was due to bacterial killing, as the number of colonies decreased over time (>log 2 over 24 h) (Fig. 2c) . A loss of membrane integrity was confirmed by decreased bacterial staining with a fluorescent membrane-potential indicator dye (Fig. 2d,e) and increased bacterial staining with an otherwise impermeable DNA dye ( Supplementary Fig. 2b,c) . IL-26 concentrations between 1 and 10 µM were required for bacterial killing, similar to the concentrations described for other cationic antimicrobial peptides such as LL-37 and hBD3 (Supplementary Fig. 2d,e) . To determine whether IL-26, like other antimicrobial peptides, kills bacteria by pore formation and membrane disruption, we used scanning electron microscopy to analyze the ultrastructure of IL-26-treated bacteria. As early as A r t i c l e s 30 min after treatment with 10 µM IL-26, we observed the formation of membrane blebs on the surface of the bacteria (Fig. 2f) . In some instances we observed disruption of the blebs with leakage of the cytosol into the extracellular environment (Fig. 2f) . These findings indicated that, similar to other cationic antimicrobial peptides, IL-26 disrupts bacterial membranes via pore formation. Although the molecular basis for the interaction of IL-26 with gram-negative and gram-positive bacteria needs to be elucidated, we found that IL-26 had the ability to bind lipopolysaccharide (LPS) from gramnegative bacteria and lipoteichoic acid (LTA) from gram-positive bacteria ( Fig. 2g and Table 2 ). Finally, we tested the antimicrobial activity of rhIL-26 in vivo using a mouse model of K. pneumoniae sepsis. This model uses intranasal administration of K. pneumoniae (O1:K2) to induce lung infection followed by rapid spreading of the bacteria into the circulation and the spleen 22 . Treatment of the mice with IL-26 resulted in significantly reduced bacterial titers in lungs, spleen and blood compared with amounts in control mice (Fig. 2h) . The in vivo antibacterial activity of IL-26 was similar to that observed with the antimicrobial peptide LL-37. A strong reduction in bacterial titers was also observed when bacteria were pretreated in vitro with IL-26, before intranasal administration (Fig. 2h) . Together, these data suggest that IL-26 is an antimicrobial protein that efficiently kills extracellular bacteria in vitro and in vivo.
T H 17 cells induce antimicrobial effects via the production of IL-26
Microarray analysis of IL-26 expression on peripheral blood cell subsets showed that IL-26 was expressed only on CD4 + T cells, and not on CD8 + T cells, NK cells, B cells, CD11c + dendritic cells, pDCs, monocyte subsets or granulocytes (Supplementary Fig. 3a) . In the CD4 + Fig. 3a ). To confirm these results, we carried out RT-PCR in in vitro-differentiated T H 17, type 0 helper T (T H 0), T H 1 and T H 2 cells under well-established polarizing conditions 23 . We found that IL26 mRNA expression was indeed high in T H 17 cells and moderate in T H 1 cells, but no expression was observed in T H 0 or T H 2 cells (Fig. 3a) . We then tested the ability of these supernatants to kill extracellular bacteria with a microbroth dilution assay. T H 17 cell supernatants but not T H 0 supernatants efficiently killed P. aeruginosa (Fig. 3b) . Bacterial growth was completely restored by the addition of a blocking antibody to IL-26, which was shown to inhibit killing of bacteria by recombinant IL-26 ( Fig. 2c-e) .
We also performed experiments with three different human T H 17 cell clones (1G3, 7H1 and 72G6) and found that supernatants derived from activated clones killed bacteria efficiently (Fig. 3c) . This activity was entirely dependent on IL-26, as small interfering RNA (siRNA)-mediated knockdown of IL-26 completely abrogated the ability of the T H 17 cell clones to kill bacteria ( Fig. 3c and Supplementary Fig. 3b ).
We noted that the concentration of IL-26 in the supernatants of both activated primary T H 17 cells and activated T H 17 cell clones ranged from 0.10 to 0.15 µM (Fig. 3d) and exerted roughly the same antimicrobial activity as 10 µM rhIL-26. This suggested that the natural IL-26 released by T H 17 cell clones has an antimicrobial potency 80-fold to 120-fold greater than that of rhIL-26 (median minimum inhibitory concentration (MIC 50 ) for rhIL-26 of 8.6 µM, versus 0.068-0.1 µM for natural IL-26) (Supplementary Fig. 4a-c) .
Collectively these data demonstrate the direct antimicrobial capacity of T H 17 cells enacted via their production of IL-26.
IL-26 promotes sensing of DNA released during bacterial killing As clustered cationic charges in antimicrobial peptides have been shown to form complexes with extracellular DNA 24 , we asked whether IL-26 binds DNA during bacterial killing. Confocal microscopy of P. aeruginosa treated with rhIL-26 showed that dying bacteria released DNA structures that formed complexes with IL-26 (Fig. 4a) . The ability of IL-26 to bind bacterial DNA was also confirmed when we mixed fragments of bacterial DNA with increasing concentrations of IL-26. IL-26, but not IL-17 or IL-22, efficiently bound to DNA, as shown by decreased staining of the DNA and retarded DNA migration in an agarose gel assay (Fig. 4b,c and Supplementary Fig. 5a ). Furthermore, we found that bacterial DNA mixed with IL-26 formed insoluble particles, but DNA mixed with IL-17 or IL-22 did not ( Fig. 4d and Supplementary  Fig. 5b ). This suggested that IL-26 is able to package and condense bacterial DNA. These IL-26-bacterial DNA particles were found to be highly protected from extracellular DNAse degradation (not shown), a process that has been shown to confer immunogenicity to DNA [24] [25] [26] [27] .
To test whether IL-26-DNA complexes are immunogenic, we tested their ability to trigger the production of inflammatory cytokines by human peripheral blood mononuclear cells (PBMCs). IL-26-DNA complexes induced the production of IL-1β, IL-6 and interferon-α (IFN-α by PBMCs), but only the production of IFN-α was significantly enhanced compared with production after stimulation with bacterial DNA alone or IL-26 alone (Fig. 4e) . To determine which cell type was responsible for the production of IFN-α, we stimulated monocytes, NK cells, neutrophils, pDCs and macrophages with IL-26-DNA complexes. Only pDCs produced high amounts of IFN-α upon stimulation with complexes (Fig. 4f) , and depletion of pDCs from PBMCs completely abrogated their ability to produce IFN-α, which indicated that pDCs are a key target of bacterial DNA-IL-26 complexes. Purified bacterial DNA alone induced weak or no IFN-α (Fig. 4f) , and IL-26 was unable to induce any IFN-α production in pDCs in the absence of DNA ( Fig. 4f and Supplementary Fig. 5c ). Thus these data demonstrate that IL-26 can form complexes with bacterial DNA and thereby promote the immunogenicity of the DNA, leading to IFN-α production by pDCs. Next we tested whether IL-26-DNA complexes generated in the context of bacterial killing also promote pDC activation. Whereas live P. aeruginosa was unable to activate pDCs, P. aeruginosa killed by IL-26 induced strong IFN-α production (Fig. 4g) . Supernatant of P. aeruginosa killed by freeze-thaw cycles was also unable to activate pDCs, but it acquired this ability when mixed with IL-26 (Fig. 4h) .
In these cultures, IFN-α production paralleled the DNA content ( Fig. 4h and Supplementary Fig. 5d ) and was completely abrogated when DNA was depleted by DNase treatment (Fig. 4i and Supplementary Fig. 5e ). These findings indicate that IL-26 has the ability to kill bacteria, bind bacterial DNA and promote immunogenicity by triggering pDC activation.
IL-26 promotes sensing of human DNA released by dying cells Because antimicrobial peptides can also promote the immunogenicity of human DNA 24-27 , we next asked whether IL-26 also kills human cells and promotes sensing of released self-DNA. We tested the ability of rhIL-26 to kill a range of human cells, including human embryonic kidney (HEK) cells and primary immune cells, but we did not observe any cytotoxic activity at 10 µM, the concentration required for efficient microbial killing (Fig. 5a) . Similarly, rhIL-26 mixed with live human cells did not induce pDC activation (Fig. 5b) . However, when rhIL-26 was mixed with irradiated human cells to trigger apoptosis and secondary necrosis, pDC activation was observed (Fig. 5b) . As expected, pDC activation was dependent on extracellular DNA released by dying human cells, as it was largely abrogated by DNase treatment of the cultures (not shown). At higher rhIL-26 concentrations, we detected cytotoxic activity on human cells similar to that described for other antimicrobial peptides such as LL-37 ( Supplementary Fig. 6a,b) . This in vitro cytotoxicity was observed at 4.9-6.6-fold the effective antimicrobial concentration for IL-26, compared to 4.0-7.6-fold that for LL-37 ( Supplementary Fig. 6a,b) . We confirmed the ability of IL-26 to bind extracellular human DNA fragments and to form particulate complexes that resembled those described for bacterial DNA (Fig. 5c,d) . Like IL-26-bacterial DNA complexes, IL-26-human DNA complexes induced preferential IFN-α production by PBMCs that was largely pDC dependent (Fig. 5e) . Human DNA induced IFN-α production in a dose-dependent manner and only in the presence of IL-26 (Fig. 5e,f) , which confirmed that IL-26 converts otherwise non-stimulatory human DNA into a potent activator of pDCs. IL-26-human DNA complexes were also found to induce some activation of monocytes, leading to the production of small amounts of IFN-α (Fig. 5e) ; this suggested broader 
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A r t i c l e s action of IL-26 in DNA-mediated innate immune activation, potentially via cytosolic DNA sensors, as monocytes do not express TLR9. Furthermore, IL-26 alone was found to trigger the production of some IL-6 and IL-1β by purified monocytes, although this activity was intrinsic to IL-26 and was not enhanced by the presence of DNA (not shown). Taken together, these data indicate that effective antibacterial concentrations of IL-26 are unable to kill human cells but do bind human DNA released in the context of cell death, leading to pDC activation.
IL-26-DNA complexes activate TLR9 in pDCs
Human pDCs specifically express TLR9, an endosomal receptor for DNA. To investigate whether IL-26 promotes immunogenicity of DNA by facilitating entry into TLR9-containing endosomal compartments, we first used fluorochrome-labeled DNA to track IL-26-DNA complexes in pDCs. We observed that IL-26-DNA complexes, but not DNA alone, rapidly associated with pDCs ( Fig. 6a) and accessed intracellular vesicular structures in those cells (Fig. 6b) . We concluded that internalization of the complexes occurred via endocytosis, as the vesicular structures expressed the early endosomal marker CD71 (Fig. 6b) and complex internalization was inhibited by culturing of pDCs either at 4 °C or in the presence of the endocytosis inhibitor Cytochalasin D (Fig. 6c,d ).
Next we investigated how IL-26-DNA complexes are endocytosed by pDCs. These cells do not express the IL-20R1 chain 28 , which means that the IL-26 receptor cannot serve as a scavenger receptor. IL-26-DNA complexes were disrupted by the addition of increasing concentrations of the anionic molecule heparin ( Supplementary  Fig. 7a ), which indicated that complex formation with the DNA is driven by the cationic residues of IL-26. Because polycation-nucleic acid complexes enter cells through heparan-sulfate proteoglycan (HSPG)-mediated endocytosis 29 , we investigated whether endocytosis of IL-26-DNA complexes is mediated by a similar mechanism. We found that internalization of the complexes was blocked both by pretreatment of pDCs with trypsin and by heparinase III (Fig. 6c,d) , which suggested that HSPGs are required for membrane attachment and endocytosis by pDCs.
To determine whether, upon endosomal entry, IL-26-DNA complexes trigger activation of TLR9, we first measured IFN-α production by pDCs pretreated with chloroquine, an inhibitor of endosomal TLR signaling. IFN-α production was completely inhibited by chloroquine (Fig. 6e) , which suggested the involvement of an endosomal TLR. IFN-α production was not inhibited when pDCs were treated with chloroquine and activated by cGAMP, which triggers the cytoplasmic sensor STING (Supplementary Fig. 8a) . Furthermore, IFN-α production was not inhibited by a neutralizing antibody to IL-10R2 that blocks activation of the IL-26 receptor 18 ( Supplementary Fig. 8b) (Fig. 6f) . Thus, we concluded that IL-26-DNA complexes are endocytosed by pDCs upon attachment to membrane HSPGs and trigger IFN-α production via activation of TLR9.
T H 17 cells promote activation of pDCs by producing IL-26 T H 17 cell supernatants containing concentrations of natural IL-26 sufficient to exert antimicrobial activity did not exert any cytotoxic activity on human cells (Fig. 5a) . However, we observed that (Fig. 7b) . To determine whether these natural IL-26-DNA complexes present in T H 17 cell supernatants trigger IFN-α production by pDCs, we stimulated purified pDCs with the T H 17 cell supernatants. Half of the T H 17 cell supernatants induced IFN-α production by pDCs (Fig. 7c,d) , and this production was inhibited by the addition of an antibody to IL-26 that blocks binding to DNA ( Supplementary  Fig. 7b ) and inhibits pDC activation (Supplementary Fig. 7c ), as well as by DNase pretreatment of the supernatants (Fig. 7e) . The other half of the T H 17 cell supernatants, which did not activate pDCs, acquired the ability to induce IFN-α production when exogenous DNA was added to the culture (Fig. 7f) , which indicated that the presence of endogenous DNA in T H 17 cell supernatants was a limiting factor for pDC activation. Supernatants of T H 17 cell clones expressing IL-26 were also able to induce IFN-α production by pDCs, and this was inhibited by siRNA-mediated knockdown of IL-26 (Fig. 7g) .
The addition of exogenous DNA to the cultures enhanced interferon production by pDCs and confirmed that activation was driven by IL-26, as interferon production by pDCs was completely blocked in knockdown experiments (Fig. 7g) . These findings suggest that T H 17 cell-derived IL-26 drives innate immune activation of pDCs through the formation of complexes with human DNA released into the extracellular environment during cell turnover. We did not observe any differences between the concentration of natural IL-26 contained in T H 17 cell supernatants and the concentration of rhIL-26 required to induce IFN-α production in pDCs (Supplementary Fig. 4c ). Both recombinant and natural IL-26 induced IFN-α production by pDCs at 0.1 µM, a concentration that seems to be relevant in vivo, as tissue concentrations of up to 0.15 µM have been measured in psoriatic skin lesions known to contain large numbers of activated pDCs producing IFN-α (ref. 30) (Fig. 7h) . 31 . As a consequence of bacterial killing, T H 17 cell-derived IL-26 also triggers potent immune activation. IL-26 binds to bacterial DNA released during the antimicrobial response and promotes internalization of the DNA into endosomal TLR9 compartments of pDCs, leading to the production of IFN-α. The mechanism underlying this process seems to be similar to the one described for the cationic antimicrobial peptide LL-37. First, IL-26 aggregates and condenses DNA fragments to form insoluble particles that are protected from extracellular degradation. Second, exposed cationic residues enable attachment of the DNA complexes to heparan proteoglycans on the cell membrane, which leads to receptor-independent endocytosis. Finally, the DNA complexes gain access to endosomal TLR9, which leads to pDC activation and the production of high amounts of type I interferons.
DISCUSSION
During microbial infections, type I interferons (IFN-α and IFN-β) can have several functions. In the context of infections caused by intracellular bacteria, type I interferons can be detrimental because of their proapoptotic activity and their ability to interfere with antibacterial mechanisms [32] [33] [34] . However, type I interferons can be beneficial in the context of infections by extracellular bacteria. Induction of type I interferon was shown to be associated with the resolution of P. aeruginosa lung infections 35 and to be required for the control of infection by Group B streptococcus, Streptococcus pneumoniae and E. coli 36 . These effects might be driven by proinflammatory functions of type I interferons 37 such as induction of dendritic cell maturation 38, 39 , promotion of CD8 + T cell activation 40, 41 and T H 1 cell differentiation 41 , activation of NK cells, and differentiation of B cells into antibody-secreting plasma cells 42 . Alternatively, type I interferon can also contribute to a beneficial disease outcome by downregulating certain inflammatory responses to bacterial infections. In fact, IFN-α production by pDCs seems to be responsible for controlling inflammation in a model of bacterial sepsis 43 . Given our findings, we speculate that IL-26 might have evolved from a pure antimicrobial protein to become a potent trigger of IFN-α production that both amplifies and regulates innate and adaptive immune responses to extracellular bacteria.
IL-26 was also found to bind fragments of extracellular human (self-) DNA and trigger IFN-α production via TLR9 activation in pDCs. This finding suggests that in addition to its antimicrobial role or as part of bacterial killing followed by binding of DNA, IL-26 also represents a danger signal that promotes IFN-α expression in injured tissue.
IL-26 is expressed in high amounts in T H 17 cell-mediated autoimmune diseases such as psoriasis 1 , inflammatory bowel disease 12 and rheumatoid arthritis 13 . These diseases are characterized by high numbers of pDCs and high IFN-α expression in tissues 30, 44, 45 , which suggests that IL-26 overexpression drives uncontrolled inflammatory responses via exaggerated IFN-α induction. As a consequence of this process, IL-26 may further enhance tissue injury by releasing self-DNA, leading to a self-sustaining inflammatory cycle that unleashes autoimmunity. Genetic evidence for a potential pathogenic role of IL-26 in these diseases is provided by the identification of a risk locus containing the gene IL26 and single-nucleotide polymorphisms within the IL26 region in subjects with rheumatoid arthritis 15 and inflammatory bowel disease 16 .
As is true of other antimicrobial peptides, high concentrations of recombinant IL-26 can kill normal human cells directly in vitro. In psoriasis, tissue concentrations of IL-26 were found to be relevant for antimicrobial and interferon-inducing activity, but not for cytotoxic activity against normal human cells. Although we cannot exclude the possibility that higher microconcentrations of IL-26 can occur in tissues, these data suggest that interferon induction in vivo might be limited to situations in which host cells are destroyed by infection or inflammation and self-DNA is already present in the extracellular environment.
The regulation of IL-26 expression in T H 17 cells is currently unknown. Analysis of in vitro-generated helper T cell subsets suggests that IL-26 expression directly parallels the expression not of IL-17, but rather of IL-22. Distinct regulation of IL-26 expression is also suggested by the fact that bacteria and bacterial products that npg A r t i c l e s trigger IL-17 expression do not lead to increased expression of IL-26 in T H 17 cells (data not shown).
Although pDCs seem to be the main target of IL-26-DNA complexes, we observed some activation of monocytes that led to the production of small amounts of IFN-α; this suggested broader implication of IL-26 in DNA-mediated innate immune activation, potentially via cytosolic STING-dependent DNA sensors as described for LL-37 (ref. 25) . Future studies will be needed to determine whether, like LL-37, IL-26 can bind extracellular RNA fragments and trigger activation of conventional DCs and monocytes via TLR8 (ref. 46) .
Our finding that the natural IL-26 in T H 17 cell supernatants is more potent than recombinant IL-26 is consistent with previously documented differences in post-transcriptional modifications between natural and recombinant proteins, including glycosylation 47 . These differences were not observed for the IFN-inducing function of IL-26, which suggests that they are selectively required to promote the antimicrobial process, as suggested by others 48 . Another possibility is that IL-26 acts in synergy with other factors in T H 17 cells to mediate antimicrobial activity.
In conclusion, this study showed that T H 17 cells, via the production of IL-26, have direct antimicrobial activity and the ability to trigger potent immune responses via the expression of type I interferon. Future strategies could be developed to modulate IL-26 function, either to enhance host antimicrobial activity or to control inflammation in response to tissue injury and in the context of autoimmune diseases.
METHODS
Methods and any associated references are available in the online version of the paper. sample by dividing the total amount of IL-26 measured in each sample by the skin-biopsy volume. The skin-biopsy volume in a cylindrical 3-mm punchbiopsy specimen was estimated as follows: h × (πr 2 ) = 3 × (π × 1.52) = 21.2 mm 3 = 21.2 µl.
Statistical analysis. For statistical analyses, we used the two-tailed unpaired Student's t-test for in vitro experiments and the unpaired non-parametric Mann-Whitney U-test for in vivo experiments and patient-sample analyses. P < 0.05 was considered significant. Group sizes, reproducibility and P values for each experiment are given in figure legends.
